Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 3;14(2):160-168.
doi: 10.3390/idr14020020.

Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial

Jose Lenin Beltran Gonzalez  1 , Mario González Gámez  1 , Emanuel Antonio Mendoza Enciso  1 , Ramiro Josue Esparza Maldonado  1 , Daniel Hernández Palacios  1 , Samuel Dueñas Campos  1 , Itzel Ovalle Robles  1 , Mariana Jocelyn Macías Guzmán  1 , Andrea Lucia García Díaz  1 , César Mauricio Gutiérrez Peña  1 , Lucila Martinez Medina  2 , Victor Antonio Monroy Colin  2 , Jose Manuel Arreola Guerra  1
Affiliations

Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial

Jose Lenin Beltran Gonzalez et al. Infect Dis Rep. .

Abstract

During the first year of the COVID-19 pandemic, unauthorized drugs were widely used. Ivermectin and hydroxychloroquine are drugs that inhibit viral replication in vitro and that have been used in several medical centers. This clinical trial analyzes their efficacy in hospitalized patients with moderate COVID-19. Methods: This a controlled, clinical, randomized, double-blind trial that included hospitalized patients with COVID-19-induced pneumonia, without severe respiratory failure. Patients were randomized to one of three groups: Group 1-hydroxychloroquine, 400 mg every 12 h on the first day and, subsequently, 200 mg every 12 h for 4 days; Group 2-ivermectin, 12 mg or 18 mg, according to patient weight; and Group 3-placebo. At inclusion, blood samples for arterial blood gases and biochemical markers were obtained. The primary outcome was established as the length of stay due to patient improvement and the rate of respiratory deterioration or death. Results: During the month of August 2020, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure, so we ended the recruitment process and analyzed the data that was available at the time. One hundred and six (106) patients with an average age of 53 yrs (±16.9) were included, with a greater proportion of males (n = 66, 62.2%). Seventy-two percent (72%) (n = 76) had an associated comorbidity. Ninety percent (90%) of patients were discharged due to improvement (n = 96). The average duration of hospitalization was 6 days (IQR, 3-10). No difference in hospitalization duration was found between the treatment groups (Group1: 7 vs. Group 2: 6 vs. Group 3: 5, p = 0.43) nor in respiratory deterioration or death (Group 1: 18% vs. Group 2: 22.2% vs. Group 3: 24.3%, p = 0.83). Conclusions: In non-critical hospitalized patients with COVID-19 pneumonia, neither ivermectin nor hydroxychloroquine decreases the number of in-hospital days, respiratory deterioration, or deaths.

Keywords: COVID-19; hydroxychloroquine; ivermectin; severe pneumonia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Time to compound outcome of death or respiratory deterioration (p = 0.44).
See this image and copyright information in PMC

References

    1. Statement on the Second Meeting of the Emergency Committee of the International Health Regulations (2005) on the Outbreak of the New Coronavirus (2019-nCoV) [(accessed on 17 October 2020)]. Available online: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting...
    1. Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R. Effects of chloroquine on viral infections: An old drug against today’s diseases. Lancet Infect. Dis. 2003;3:722–727. doi: 10.1016/S1473-3099(03)00806-5. - DOI - PMC - PubMed
    1. Geleris J., Sun Y., Platt J., Zucker J., Baldwin M., Hripcsak G., Labella A., Manson D.K., Kubin C., Barr R.G., et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2020;382:2411–2418. doi: 10.1056/NEJMoa2012410. - DOI - PMC - PubMed
    1. Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C., Veiga V.C., Avezum A., Damiani L.P., Marcadenti A., Kawano-Dourado L., Lisboa T., et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N. Engl. J. Med. 2020;383:2041–2052. doi: 10.1056/NEJMoa2019014. - DOI - PMC - PubMed
    1. Boulware D.R., Pullen M.F., Bangdiwala A.S., Pastick K.A., Lofgren S.M., Okafor E.C., Skipper C.P., Nascene A.A., Nicol M.R., Abassi M., et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N. Engl. J. Med. 2020;383:517–525. doi: 10.1056/NEJMoa2016638. - DOI - PMC - PubMed

LinkOut - more resources